NCT07109414View on ClinicalTrials.gov

Trial of NP-G2-044 (Prilukae) Combined With PLD for Treatment of Platinum-Resistant Ovarian Cancer (ULTIMUS-1)

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

August 29, 2025

Primary Completion Date

October 25, 2028

Study Completion Date

October 24, 2029

Conditions
Platinum-resistant Ovarian Cancer
Interventions
DRUG

NP-G2-044

NP-G2-044 will be provided as a tablet via oral route of administration in the study.

DRUG

PLD

PLD will be provided as an infusion via intravenous route of administration in the study.

Trial Locations (1)

71133

RECRUITING

Trials365, Shreveport

Sponsors
All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

Novita Pharmaceuticals, Inc.

INDUSTRY